Inhibitors of histone deacetylases (HDACs) are nowadays part of the therapeutic arsenal
mainly against cancers, with four compounds approved by the Food and Drug …

Covering: up to 2014 Marine cyanobacteria are an ancient group of organisms and prolific
producers of bioactive secondary metabolites. These compounds are presumably optimized …

Tubulin-targeted chemotherapy has proven to be a successful and wide spectrum strategy
against solid and liquid malignancies. Therefore, new ways to modulate this essential …

Histone deacetylases (HDACs) play a crucial role in the remodeling of chromatin, and are
involved in the epigenetic regulation of gene expression. In the last decade, inhibition of …

This Review is devoted to the chemistry of macrocyclic peptides having heterocyclic
fragments in their structure. These motifs are present in many natural products and synthetic …

Cancer is one of the leading causes of death in the world, and antineoplastic drug research
continues to be a major field in medicine development. The marine milieu has thousands of …

Increasing disease-related proteins have been identified as novel therapeutic targets.
Macrocycles are emerging as potential solutions, bridging the gap between conventional …

Background The genome-wide hyperacetylation of chromatin caused by histone
deacetylase inhibitors (HDACi) is surprisingly well tolerated by most eukaryotic cells. The …

The marine environment is host to unparalleled biological and chemical diversity, making it
an attractive resource for the discovery of new therapeutics for a plethora of diseases …

Worldwide, 19.3 million new cancer cases and almost 10.0 million cancer deaths occur each
year. Recently, much attention has been paid to the ocean, the largest biosphere of the earth …